compare semaglutide and tirzepatide vs vs retatrutide: the complete three-way comparison Not all GLP-1s are the
Description
Ongoing outcome clinical trials in other groups of patients and more detailed mechanistic studies will shed further light on the mechanisms of cardiovascular benefit with SGLT2 inhibitors
Pro tip: Not a fan of the taste straight
National Heart, Lung, and Blood Institute: Atherosclerosis
However, a new trend is emerging: GLP-1 patches
Oct 9: In a relatively rare move, the FDA went against the recommendation of one of its advisory committees, rejecting a bid by Alnylam to expand Onpattro (patisiran)s label to cardiomyopathy of transthyretin-mediated amyloidosis
Neumiller JJ, et al
